Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. - Wikidata - wikimedia - TriplyDB

Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.

Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.

http://www.wikidata.org/entity/Q53046021

about

The current trend of administering a patient-generated index in the oncological setting: a systematic review Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach Patient-reported outcome measures in inflammatory bowel disease.A brief symptom index for advanced lung cancer.Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology?Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22).Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index.A new index of priority symptoms in advanced ovarian cancer.

P2860

Q26823678-370BAE59-A47B-4569-9908-B9CDDF19DC42 Q28655361-9E2906A0-2FC0-4B29-8FE8-1ABF701162E7 Q34488943-84E0E73C-422F-4F6B-A7A5-A01EA1B69CA5 Q34524596-64D4059F-E115-49DE-BBE8-2A98ED4ACC92 Q35801735-65BD258D-5188-4D8C-BD8F-F042B4064B69 Q36179711-552D0A1E-0DE4-4601-B6D6-EABEF96B9A22 Q36927798-26770766-14CE-4468-84C6-3E81D98E7C54 Q39970827-E24B0442-3E3F-43E7-932C-97C3AFFDEAEC Q43923570-490871A0-B2D5-48AD-AA58-8A1D6BAEFF5C Q46448007-9F181BAE-D1B9-4957-B881-B27E71F932BC Q46859743-32D8EFAE-9AE0-4ECD-9FE8-9EB09A9F2BBE Q47616622-2AC6F6AF-940D-42C6-A320-5F221D26D3A7 Q47650247-65579FBE-7364-4F5A-8723-AE774654DC4E Q48187114-4849860B-1F0E-471C-B14A-E5F3953092B6 Q48367978-46072217-B557-468E-8553-0301CA397821 Q48762319-DFF58D61-DEDB-4CEB-88E7-FF396A54047D

P2860

Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.

http://www.wikidata.org/entity/Q53046021

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Development and validation of ...... motherapy for advanced cancer.

@en

Development and validation of ...... motherapy for advanced cancer.

@nl

type

label

Development and validation of ...... motherapy for advanced cancer.

@en

Development and validation of ...... motherapy for advanced cancer.

@nl

prefLabel

Development and validation of ...... motherapy for advanced cancer.

@en

Development and validation of ...... motherapy for advanced cancer.

@nl

P1433

Q53046021-0C006F6D-7506-46D6-8711-97BE354D3702

P1476

Q53046021-952C8D22-4178-4D61-B6F8-96EAAE2A00F3

P2093

Q53046021-0490F178-A6F1-4566-AE56-E831695D7C4E

Q53046021-26D57C95-E104-493D-9437-780FACB5E2CA

Q53046021-2B41AAA0-584C-4083-A017-87A93E839290

Q53046021-51468C29-8B5C-4771-9852-FDD2E060422A

Q53046021-761DF33F-2343-4F3A-B8B9-DA3D96EF32A9

Q53046021-8C3D9D97-3ACC-4657-84B2-B66C89D3D819

Q53046021-B1E55A30-2FDF-4360-9437-8D7C27F2EF8F

Q53046021-B8281289-8CE2-4B58-A450-EA33B403B140

P2860

Q53046021-1576CB2F-A870-48AD-93DC-5C29347F4334

Q53046021-18D0A3C8-80CA-4C0E-84C4-7E99BAAFE199

Q53046021-1E554719-5EBA-4074-A652-8FC7F3748CDF

Q53046021-38FA0B5A-E668-4DD7-ABEE-EA54F9265AE5

Q53046021-3A3C6BF3-F582-4186-A850-1A9BCE2AF817

Q53046021-3E094F84-E127-4F4F-A07C-68E19E03F99E

Q53046021-4070B581-D635-40C8-ACB4-1969304A18E9

Q53046021-429CE162-A89B-4052-B9E9-50EFBB5998AC

Q53046021-44190BBC-EA6E-430A-B023-768176D872E6

Q53046021-4E4EE7F4-CB2D-46D1-BA26-23B956770DA9

P304

Q53046021-B940856E-281F-4DCB-956E-A94D874D478F

P31

Q53046021-1610F201-BAE0-42D3-978F-E22A6A75D631

P356

Q53046021-A274963B-6FEC-493C-83A5-C7F8862F7FF6

P433

Q53046021-A6077251-8E45-4DAD-B03E-1CB523C35A1F

P478

Q53046021-B25B4C51-55CB-437B-9CC7-E2AA7B12773D

P50

Q53046021-039A4830-F08B-4CF7-B487-FFADC9382D65

Q53046021-7FE3692A-F7AA-4BD2-93E2-DD6D535B4001

P577

Q53046021-99D8D219-F5A0-426F-8EA7-CEFE8DE9FDB9

P698

Q53046021-38935C38-604B-4210-A261-BB2C5F358B8A

P921

Q53046021-F20F4D32-ADCC-4533-87DB-9771CCA2D798

P932

Q53046021-8A401FE9-BB03-4CCD-915E-2ED9C0CB9B27

P356

JNCCN.2011.0026

P1433

Journal of the National Comprehensive Cancer Network

P1476

Development and validation of ...... motherapy for advanced cancer.

@en

P2093

Debra Hampton

http://www.w3.org/2001/XMLSchema#string

Diane Paul

http://www.w3.org/2001/XMLSchema#string

Jamie H Von Roenn

http://www.w3.org/2001/XMLSchema#string

Jennifer L Beaumont

http://www.w3.org/2001/XMLSchema#string

Karen Syrjala

http://www.w3.org/2001/XMLSchema#string

Paul B Jacobsen

http://www.w3.org/2001/XMLSchema#string

Sarah K Rosenbloom

http://www.w3.org/2001/XMLSchema#string

Susan E Yount

http://www.w3.org/2001/XMLSchema#string

P2860

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

The use of quality of life data in clinical practice.

Quality of life issues in the management of ovarian cancer.

Quality-of-life end points in oncology drug trials.

A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

A critical appraisal of the quality of quality-of-life measurements.

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Development of a comprehensive quality of life measurement tool: CARES.

Barriers to the use of health status measures in clinical investigation, patient care, and policy research.

The measurement of health status in clinical practice.

P304

268-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2011.0026

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Amy P. Abernethy

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21393439

http://www.w3.org/2001/XMLSchema#string

P921

P932

5865593

http://www.w3.org/2001/XMLSchema#string